Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction
Author | Kaddoura, Rasha |
Author | Abushanab, Dina |
Author | Arabi, Abdul Rahman |
Author | Alyafei, Sumaya Alsaadi |
Author | Al-Badriyeh, Daoud |
Available date | 2023-05-11T04:02:27Z |
Publication Date | 2022-12-01 |
Publication Name | Current Problems in Cardiology |
Identifier | http://dx.doi.org/10.1016/j.cpcardiol.2022.101385 |
ISSN | 01462806 |
Abstract | Although previous cost‐effectiveness evaluations of sacubitril/valsartan have demonstrated cardiovascular and economic benefits in heart failure patients with reduced ejection fraction (HFrEF), whether sacubitril/valsartan is cost-effective for reducing the need for implantable cardioverter-defibrillator (ICD) implantation and the risk of death in ICD‐eligible patients has not been investigated in patients with HFrEF. Herein, we evaluated the cost-effectiveness of sacubitril/valsartan versus standard of care in reducing the need for ICD implantation and the death rate in HFrEF. A Markov model was developed from the Qatari hospital perspective, comprised of ‘survival’ and ‘death’ health states, and was based on 1-monthly Markovian cycles, a 20-years follow-up horizon, and a 3% discount rate. The model inputs were obtained from the literature and local sources. Sacubitril/valsartan resulted in a relative increase of 0.04 quality-adjusted life year (QALY) and 0.67 years of life lived (YLL)/person, with an incremental cost increase of QAR13,952 (USD3,832). Sacubitril/valsartan was associated with incremental cost effectiveness ratio of QAR341,113 (USD93,687)/QALYs gained and QAR24,431 (USD6,710)/YLL. Sensitivity analyses confirmed robustness, with the cost-effectiveness maintained in ≥96.5% of simulated cases. To conclude, sacubitril/valsartan is a cost-effective alternative to standard care against QALY gained and YLL in reducing the need for an ICD therapy and the rate of death among ICD-eligible HFrEF patients. |
Language | en |
Publisher | Elsevier |
Subject | Sacubitril/Valsartan Implantable Cardioverter-Defibrillator (ICD) |
Type | Article |
Issue Number | 12 |
Volume Number | 47 |
Check access options
Files in this item
This item appears in the following Collection(s)
-
Pharmacy Research [1261 items ]